Marvin S. Hausman MD

Filings by Marvin S. Hausman MD span 3 companies, the busiest being Entia Biosciences, Inc., GT Biopharma, Inc. and Ludwig Enterprises, Inc. The record holds 18 filings, for trades running from 12 October 2006 to 29 April 2026.

On the open market, the record shows 3 purchases worth €564k and 2 sales worth €34k. On balance, insiders were net buyers of €530k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 13 share grants. Since January 2026: no purchases and 2 sales on the market.

In size, the median ticket on the buying side is €38k. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +13.6%. This is a record of the past, not a forecast.

The newest entry dates from 1 May 2026: an open-market sale of €25k, in Ludwig Enterprises, Inc. The last insider purchase was made public on 12 November 2014, 4,379 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.